Dear Label_Name,

Greetings! I hope you are well.

I am writing on behalf of an international publishing house, Science and Education Publishing, USA (http://www.sciepub.com).

Science and Education Publishing (SciEP) is a multidisciplinary open access publisher of Journals covering the fields of Science, Technology and Medicine. All SciEP publications are subject to high-quality peer review, editorial and production processes and are freely available online.

Welcome to the April, 2013 edition of SciEP newsletter, providing monthly summaries of articles on science & education related topics of interest to scientist and professionals. The mission of our journals is to provide an open access forum for publishing new findings on issues pertinent to scientific and academic field. We also invite you to submit original research papers, review articles, short reports, or case studies are considered for publication in our Multidisciplinary Journals.

American Journal of Public Health Research
DOI: 10.12691/ajphr-1-1-3

The Implementation of a Tele-Homecare System with Service Oriented Architecture and HL7 Message Transmission Standard
Ching-Sung Wang

American Journal of Medical and Biological Research
DOI: 10.12691/ajmbr-1-1-2

The Influence of Ethanol on Pyruvate Kinases Activity in Vivo, in Vitro, in Silico
Lelevich Sergey Vladimirovich, Khrustalev Vladislav Victorovich, Barkovsky Eugene Victorovich, Shedogubova Tatyana Aleksandrovna

American Journal of Medical Sciences and Medicine
DOI: 10.12691/ajmsm-1-1-1

Clinical and Histological Features in Wegener Granulomatosis
Li Cavoli Gioacchino, Passantino Rita, Bono Luisa, Tortorici Calogera, Ferrantelli Angelo, Giammarresi Carlo, Rotolo Ugo

American Journal of Infectious Diseases and Microbiology
DOI: 10.12691/ajidm-1-1-2

The Curse of Lymphatic Filariasis: Would the Continual Use of Diethylcarbamazine Eliminate this Scourge in Papua New Guinea?
Anne Lanham, Lillian Mwanri

We have released issues of some journals on February 2013.
American Journal of Public Health Research
American Journal of Medical Sciences and Medicine
American Journal of Medical and Biological Research
American Journal of Pharmacological Sciences
American Journal of Clinical Medicine Research
American Journal of Nursing Research
American Journal of Cancer Prevention
American Journal of Medicine Studies
American Journal of Infectious Diseases and Microbiology
American Journal of Cardiovascular Disease Research
American Journal of Biomedical Research
American Journal of Mechanical Engineering
American Journal of Microbiological Research
Journal of Preventive Medicine
American Journal of Food and Nutrition
American Journal of Hypertension Research
American Journal of Sports Science and Medicine
Journal of Cancer Research and Treatment
American Journal of Zoological Research
Journal of Biomedical Engineering and Technology
American Journal of Microbiological Research
Biomedical Science and Engineering

We are pleased to announce that submissions are now being accepted for peer review for all the journals across all our subject areas in SciEP.

Please submit your manuscript via our online submission system:
http://www.sciepub.com/author/signin

To unsubscribe from our mailing list, please click on the following link: unsubscribe

I am looking forward to hearing from you.

Kind regards,

David Rain
Email:join@sciepub.com
Science and Education Publishing (http://www.sciepub.com)

Prevalence of Hepatitis C at a Primary Hospital in the Western Region of Ghana

Kwamena Kwentsir Daniels*, Prince Kenneth Homiah, Bernice Ameyaw, Ebenezer Mensah Turkson, Valerie Asare-Baffour, Dr George T. Tidakabi, Dr Ishmael Yamoah, Esthella Shieley Ashitey, Eunice Ama Kwofie, Michael Korabo, Benjamin Oppong Nyantakyi, Samuel Bekoe

Laboratory, Ghana Ports and Harbours Authority, Takoradi, Ghana

Abstract: Background: Hepatitis C infection can often be detected by antibodies to the hepatitis C virus. HCV infection frequently goes untreated since it is asymptomatic for decades before symptoms appear as a result of severe liver damage. This study will investigate the prevalence of HCV in the Western region, specifically the Sekondi-Takoradi metropolis. The research sought to improve the knowledge gap by providing data on the prevalence rates of HCV. Methods: 980 samples collected from January to April 2022 were subjected to a retrospective analysis. The HCV serologic test was performed using the one-step immune-chromatographic test kit. Age-related data and the results of all serologic tests for HCV were recorded and evaluated during analysis. Results: A total number of 980 samples were analyzed in this study. Out of which 91.3% (n=895) were seronegative and the remaining 8.7% (n=85) were seropositive. Seropositivity was mainly found significantly among the 35-44, <15, and 24-34-year age groups with 2.7%, 1.9%, and 1.7% positivity rates respectively Age-specific prevalence rates were significantly high among the 35-44 and ≥55-year age groups with positivity rates of 13.8% and 8.3%. Also, the age-specific prevalence was high among the <15, 25-34, and 15-24-year age groups with positivity rates of 7.6%, 7.4%, and 7.3% respectively. Conclusion: This study recorded a high prevalence rate of HCV seropositivity. To the best of our knowledge, this is the first study in the Western region to have considered HCV prevalence. The findings emphasize the necessity for quick public health measures to lower infection rates. These must target screening of high-risk groups, education campaigns about HCV transmission patterns, and the provision of treatment for those who are infected.

Keywords: Hepatitis C, Seropositivity, prevalence

Received January 02, 2023; Revised February 03, 2023; Accepted February 09, 2023

Citation: Kwamena Kwentsir Daniels, Prince Kenneth Homiah, Bernice Ameyaw, Ebenezer Mensah Turkson, Valerie Asare-Baffour, Dr George T. Tidakabi, Dr Ishmael Yamoah, Esthella Shieley Ashitey, Eunice Ama Kwofie, Michael Korabo, Benjamin Oppong Nyantakyi, Samuel Bekoe, Prevalence of Hepatitis C at a Primary Hospital in the Western Region of Ghana. American Journal of Infectious Diseases and Microbiology, 11 (1). 8-12. January 2023. doi:10.12691/ajidm-11-1-2

1. Introduction

Infection with the hepatitis C virus (HCV) is now recognized as having a substantial impact on global health, impacting all nations, and necessitating the necessary care. The World Health Organization reports about 58 million people with chronic hepatitis C globally out of which 3.2 million belong to the adolescent and children group. In 2019, an estimated 290,000 people died from hepatitis C [1]. It is commonly acknowledged that more work has to be done to control the condition, even if recent estimates indicate a reducing burden mostly because of a decline in prevalence among youngsters. HCV infection can often be detected by antibodies to HCV (anti-HCV). To compare HCV infection rates around the world, population-based studies' findings on the prevalence of anti-HCV are employed.

Hepatitis C is often associated with liver cirrhosis, fibrosis, and hepatocellular carcinoma (HCC) which could advance to hepatic failure [2]. About 30% of hepatitis C infections resolve after 6 months while the remaining 70% become chronic. At about 20 years post hepatitis C infection, 15% to 30% of chronically infected persons may develop HCC [1]. Chronic HCV infection is responsible for around 25% of liver cirrhosis and HCC cases worldwide, with rates being greater in endemic areas [3].

The prevalence of hepatitis C varies from 0.5% to 2.5%. Eastern Mediterranean and Europe have very high prevalence rates [4]. According to WHO regional demarcations, the American region has the least number of hepatitis C infections followed by the African region [1]. However, Africa has recorded very high rates of 2.8% close to a decade ago [5]. With low surveillance and monitoring systems in Ghana and across the African continent, over-estimation or underestimation of disease occurrence is inevitable.

Hepatitis C does not affect only adults. Children and adolescents also get infected although the rate is minimal. The global prevalence rate of the disease among children aged 1 – 19 years is 0.15% [6]. The effect of the disease is low among this population with hepatocellular carcinoma being rare.

It is crucial to emphasize that there are several significant obstacles to accurately documenting the burden of HCV to determine the disease's genuine incidence and prevalence in any given nation [6]. Assays that can differentiate between acute and chronic infections are not readily available, for example, and the majority of acute HCV infections frequently have no symptoms. There is insufficient data on HCV prevalence in Ghana. The current data on the nation’s prevalence according to Agyeman [7] was 3%. Studies on the regional prevalence of HCV are also limited. Akyar [8] reported Accra’s HCV prevalence to be 6.4%.

Hence, it will be important for researchers to focus on the regional prevalence of the disease which could aid in a national aggregate of HCV prevalence. This study will investigate the prevalence of HCV in the Western region, specifically the Sekondi-Takoradi metropolis. The research sought to improve the knowledge gap by providing data on the prevalence rates of HCV at a primary health facility, Ghana Ports and Harbours Authority Hospital (GPHA) in the Western region of Ghana.

2. Methods

2.1. Study Design and Setting

This was a retrospective study involving selected samples drawn from patients who attended GPHA hospital - Takoradi, from January to April 2022. The inclusion criteria were all EDTA samples collected within the period of study. Ethical clearance and data were sought and acquired from the management of the facility. Retrieved data were kept anonymous. 980 samples were analyzed for this study with ages 2 years and above and no gender limitations. The average age was 30 years old and they consisted of 410 (41.8%) males and 570 (58.2%) females. Of these, 23.4% (n=229) were in the 25-34-year age group. Only 8.3% (n=81) of the entire population were in the 15-24-year bracket, and a greater number were in the <15-year group (Figure 1).

Figure 1. Age distribution among the study population

2.2. Serological Screening

The HCV serologic test was performed using the one-step immune-chromatographic test kit (Wondfo, Sensitivity = 99%, Specificity = 99.8%).

The following assay protocol was used by the manufacturer: Using a plastic dropper included in the pouch, 10 µL of plasma volume was applied to the upper edge of the test strip's sample pad. Two drops of the diluent were then put on the lower edge. After fifteen minutes, the results were read and interpreted after 15 minutes. Any results after 20 minutes were not read since they can cause erroneous results.

2.3. Statistical Analysis

All patient demographics including ages and test results (seropositive/negative) were originally recorded and input for analysis into Microsoft Excel, 2016. Age-related data and the results of all serologic tests for HCV were evaluated.

3. Results

A total number of 980 samples were analyzed in this study. Out of which 91.3% (n=895) were seronegative and the remaining 8.7% (n=85) were seropositive (Figure 2). Out of the analyzed samples, 5.1% (n=50) of females and 3.6% (n=35) were seropositive (Figure 3).

Figure 2. Total summary of tests results

Figure 3. Gender distribution of HCV seropositives

In all, the seropositivity was mainly found significantly among the 35-44, <15, and 24-34-year age groups with 2.7%, 1.9%, and 1.7% positivity rates respectively. Age-specific prevalence rates were significantly high among the 35-44 and ≥55-year age groups with positivity rates of 13.8% and 8.3% respectively. (Table 1). Age-specific prevalence was also high among the <15, 25-34, and 15-24-year age groups with positivity rates of 7.6%, 7.4%, and 7.3% respectively.

Table 1. Sero-prevalence of HCV among the study population

4. Discussion

In this study, the authors recorded a high HCV prevalence of 8.7 % among study subjects. These findings may not be representative of the regional HCV prevalence in the Western region of Ghana. Though the hospital receives clients from almost all districts in the region, data on the study subjects’ districts were not available. An 8.7% positivity rate is significantly higher than the 6.4% recorded in Akyar [8] and the 3.0% national HCV prevalence reported by Agyemang [7]. This wide prevalence variation corresponds with Layden’s [5] assertion that Africa’s prevailing HCV prevalence data may be underestimated.

HCV infection is known to be high among human immune deficiency virus (HIV) infected persons [9]. The Western region is among the regions in Ghana with a high HIV prevalence rate [10]. This reason could partially account for the high HCV prevalence in the region. Future studies should focus on HCV prevalence among risk groups.

In our study, most of the positivity rate lay within the 25-34 age group (1.7%) and 35-44 age group (2.7%). HCV infection among young adults is seen in people who inject drugs [11]. Sexually active individuals are also at risk. It is not surprising that this study recorded a high prevalence rate among young adults. In Ghana, HCC can develop at a young age [12]. About 1 in 14 cirrhosis cases in Ghana is caused by HCV [13]. About 8.8% of deaths among Ghanaian adults are liver-related of which HCV infection is responsible for 8.8% [14]. Therefore, HCV infection should be a concern for everyone. Stakeholders should commit to taking action to combat this disease. High HCV prevalence is anticipated to affect economic growth since infected individuals' general wellness and output are likely to suffer. Considering the effect HCV can have on Ghana’s economy, the government needs to give adequate attention to the fight against the illness.

Though this study did not limit the population to pregnant women, the study analyzed samples that included those of pregnant women. Hence, the 8.7% prevalence recorded in this study raises an alarm among the pregnant women population. HCV infection among pregnant women exposes them to the risk of preterm birth, low birth weight, congenital abnormalities, pregnancy-related glucose intolerance, and overall perinatal mortality [15,16]. This is an important issue since the infected can transmit to their children, vertical transmission. Due to the potentially high incidence of HCV among pregnant women, Ghana needs to implement a national program that includes HCV screening as part of anti-natal routine lab tests.

Given the high frequency of other viral hepatitis in Ghana and the high prevalence of chronic HCV infection, there is rising worry about the safety of blood products [17]. A greater focus and stricter surveillance will be required to ensure high levels of compliance with the national blood policy to minimize the risk of transfusing contaminated blood to patients. Even though Ghana has a national blood policy requiring that all donated blood be tested for blood-borne infections such as HIV 1 and 2, Hepatitis B (HBV), HCV, and Syphilis, most laboratories rely heavily on antibody rapid diagnostic tests. More specific tests like antigen and polymerase chain reaction (PCR) should be encouraged for screening donors.

The high rates of chronic HCV infection in the Western region could be a result of low knowledge about the disease. According to studies, Ghanaians are not very knowledgeable about hepatitis transmission routes. For instance, Mutocheluh and Kwarteng [18] found that among 200 barbers in Kumasi, 0% of the barbers could characterize the major HCV transmission pathways, and only 7% were aware that sharing razor blades or hair trimmers could be a mechanism of spreading viral infections like HCV and HBV. For pregnant women, similar patterns of decreased awareness have been noted [19]. In many Ghanaian communities, there has been an overemphasis on HCV and associated viral hepatitis as sexually transmitted illnesses (STIs), even though the mechanisms of HCV transmission are diverse. These include unprotected intercourse, mother-to-child transmission, and transfusion of infected blood [20]. Such beliefs about HCV’s mode of transmission usually become a barrier to properly seeking medical attention.

There is presently no vaccine for HCV infection worldwide, though antiviral medications are available - depending on the type of HCV genome. As a result, public education is a good strategy for promoting disease awareness, transmission routes, early diagnosis, and treatment of infected individuals. Increasing understanding and awareness of the disease's transmission routes and also, early detection and treatment of sick individuals, would be the primary strategy for interrupting infection transmission through risk reduction.

5. Limitations

This study encountered the following limitations:

1. This study cannot be generalized to the entire Ghanaian population since it focused on subjects located in the Western region.

2. Confirmatory tests for RDT-positive cases were not available to the authors.

3. Socio-demographic data on subjects’ district of residence and antenatal status could not be retrieved.

6. Recommendations

To better understand the HCV burden in Ghana, future research should focus on the epidemiology of HCV in Ghana and among certain high-risk populations. Further studies are needed to ascertain what is accountable for the high HCV prevalence observed in this study. Lastly, the National Health Insurance Scheme (NHIS) Medicines List can then be updated to include medications for HCV treatment.

7. Conclusion

We recorded an 8.7% HCV prevalence at the end of our study. To the best of our knowledge, this is the first study in the Western region to have considered HCV prevalence. The findings emphasize the necessity for quick public health measures to lower infection rates. This report offers a means of educating stakeholders and policymakers about the imperative need to advance treatment access and HCV infection prevention efforts worldwide. These must target screening of high-risk groups, education campaigns about HCV transmission patterns, and the provision of treatment for those who are infected.

Acknowledgments

The authors would like to thank Management especially, Captain Ebenezer Afadzi (GPHA Director of Port, Takoradi) and the hospital management at GPHA hospital, Takoradi.

References

[1]   | World Health Organisation (2022). Hepatitis C. Available: https://www.who.int/news-room/fact-sheets/detail/hepatitis-c#:~:text=Globally%2C%20an%20estimated%2058%20million, new%20infections%20occurring%20per%20year. (Accessed on: 28 November 2022).
[2]   | Khatun, M. and Ray, R.B., 2019. Mechanisms underlying hepatitis C virus-associated hepatic fibrosis. Cells, 8(10), p.1249.
[3]   | Averhoff FM, Glass N, Holtzman D. Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis. 2012; 55 Suppl 1: S10-5.
[4]   | Brunner N, Bruggmann P. Trends of the Global Hepatitis C Disease Burden: Strategies to Achieve Elimination. J Prev Med Public Health. 2021 Jul; 54(4): 251-258.
[5]   | Layden JE, Phillips R, Opare-Sem O, Akere A, Luke A, Tayo BO, Cooper RS. Hepatitis C in sub-Saharan Africa: urgent need for attention. Open Forum Infect Dis. 2014; 1(2): ofu065.
[6]   | Indolfi, G., Easterbrook, P., Dusheiko, G., El-Sayed, M.H., Jonas, M.M., Thorne, C., Bulterys, M., Siberry, G., Walsh, N., Chang, M.H. and Meyers, T., 2019. Hepatitis C virus infection in children and adolescents. The Lancet Gastroenterology & hepatology, 4(6), pp.477-487.
[7]   | Agyeman, A. A., Ofori-Asenso, R., Mprah, A., & Ashiagbor, G. (2016). Epidemiology of hepatitis C virus in Ghana: A systematic review and meta-analysis. BMC Infectious Diseases, 16(1).
[8]   | Akyar Eda, Mora Nallely, Luke Amy, Layden Jennifer, Phillips Richard, Agyarko-Poku Thomas et al. 2203. Risk Factors for Hepatitis C in Western Africa: An Observational Study in an STI Clinic. Open Forum Infectious Diseases. 2018; 5(suppl_1): S650-S. PubMed| Google Scholar.

[9]  
Susanna Naggie, Daniel S Fierer, Michael D Hughes, Arthur Y Kim, Annie Luetkemeyer, Vincent Vu, Jhoanna Roa, Steve Rwema, Diana M Brainard, John G McHutchison, Marion G Peters, Jennifer J Kiser, Kristen M Marks, Raymond T Chung, Acquired Immunodeficiency Syndrome Clinical Trials Group (ACTG) A5327 Study Team, Ledipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals, Clinical Infectious Diseases, Volume 69, Issue 3, 1 August 2019, Pages 514-522.

[10]   | Ali H, Amoyaw F, Baden D, Durand L, Bronson M, Kim A, Grant-Greene Y, Imtiaz R, Swaminathan M. Ghana's HIV epidemic and PEPFAR's contribution towards epidemic control. Ghana Med J. 2019 Mar; 53(1): 59-62.
[11]   | Jost, J.J., Tempalski, B., Vera, T., Akiyama, M.J., Mangalonzo, A.P. and Litwin, A.H., 2019. Gaps in HCV knowledge and risk behaviors among young suburban people who inject drugs. International journal of environmental research and public health, 16(11), p.1958.
[12]   | Yang JD, Mohammed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol 2017; 2: 103-11.
[13]   | Blankson A, Wiredu EK, Adjei A, Tettey Y. Seroprevalence of hepatitis B and C viruses in cirrhosis of the liver in Accra, Ghana. Ghana Med J 2005; 39(4): 132-7.
[14]   | Nartey, Y.A., Antwi, S.O., Bockarie, A.S., Hiebert, L., Njuguna, H., Ward, J.W., Awuku, Y.A., Plymoth, A. and Roberts, L.R., 2022. Mortality burden due to liver cirrhosis and hepatocellular carcinoma in Ghana; the prevalence of risk factors and predictors of poor in.
[15]   | Pergam SA, Wang CC, Gardella CM, Sandison TG, Phipps WT, Hawes SE. Pregnancy complications associated with hepatitis C: data from a 2003–2005 Washington state birth cohort. Am J Obstet Gynecol. 2008; 199: 38. e1-38. e9.

[16]  
Reddick, K. L., Jhaveri, R., Gandhi, M., James, A. H., & Swamy, G. K. (2011). Pregnancy outcomes associated with viral hepatitis. Journal of viral hepatitis, 18(7), e394–e398. The Global burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol. 2004; 44: 20-9.

[17]   | Ofori-Asenso R, Agyeman A. Hepatitis B in Ghana: a systematic review and meta-analysis of prevalence studies (1995–2015). BMC Infect Dis. 2016; 16(1): 130.
[18]   | Mutocheluh M, Kwarteng K. Knowledge and occupational hazards of barbers in the transmission of hepatitis B and C was low in Kumasi, Ghana. Pan Afr Med J. 2015; 20: 260.

[19]  
Cheng A, Jose J, Larsen-Reindorf R, Small C, Nde H, Dugas L, Ehrhardt S, Nelson K, Ezeanolue E, Layden J. A survey study of pregnant women and healthcare practitioners assessing the knowledge of attitudes and practices of hepatitis B management at a teaching Hospital in Kumasi, Ghana, West Africa. Open Forum Infect Dis. 2015; 2(4): ofv122.

[20]   | Adler M, Goubau P, Nevens F, Van Vlierberghe H. Hepatitis C virus: the burden of the disease. Acta Gastroenterol Belg. 2002; 65: 83-6.